期刊文献+

建立糖尿病心肌病动物模型方法的实验研究 被引量:38

A method to produce the animal model of diabetic cardiomyopathy
在线阅读 下载PDF
导出
摘要 目的研究建立糖尿病心肌病动物模型的科学、实用的方法。方法应用链脲佐菌素对SD大鼠进行一次性腹腔注射,通过观察大鼠的一般状况、进食量、进水量、尿量、体重的变化,监测血糖、尿糖、心肌酶含量、胰岛素水平、心肌超微结构、心脏大血管内膜情况及心电图情况来评估糖尿病心肌病的发病情况。结果腹腔注射STZ 3周后,模型组大鼠出现病态表现,进食量、饮水量、尿量增加,体重下降。血糖值、尿糖值及肌酸激酶、乳酸脱氢酶值均较对照组大鼠升高。胰岛素水平较对照组明显降低,心肌超微结构符合糖尿病心肌病表现,心脏大血管未见纤维斑块和粥样斑块。结论对SD大鼠进行一次性腹腔注射链脲佐菌素(55mg/kg),大鼠于注射后第3周可出现稳定的糖尿病心肌病状态。这是一种可靠且实用性强的糖尿病心肌病动物模型的制备方法。 Objective To study a simple and scientific method to produce the animal model of diabetic cardiomyopathy. Methods Injecting the streptozotocin (STZ) liquid at the left iliac region only once in the model group, observing the general condition, the change of eating level, drinking level, urine level and weight, examining the level of creatine kinase(CK-MB), lactate dehydrogenase( LDH-1 ), insulin, blood sugar and urine sugar. Observe the cardiac muscle ultrastructure, the large vessel tunica intima and electrocardiogram. Results After injecting the STZ 3 weeks, the model rats appear morbid, the value of eating, drinking, urine are increased and weight decreased. The model rat blood sugar, urine sugar, CK and LDH levels are higher than control rat. The model rat insulin level is lower than control group. The model rat cardiac muscle uhrastructure accord with the diabetic cardiomyopathy' s, and the fibrous or atheromatous plaque do not been found at the large vessel tunica intima. Conclusion The SD model rat appear the diabetic cardiomyopathy condition by injected the STZ (55mg/kg)at the left iliac region only once in 3 weeks. It is a simple and scientific method to produce the animal model of diabetic cardiomyopathy.
出处 《卫生研究》 CAS CSCD 北大核心 2006年第6期707-711,共5页 Journal of Hygiene Research
基金 国家自然科学基金资助(No.30270554 39970273) 教育部高校士学科点基金资助(No.2005698012) 教育部高等学校科技创新工程重大项目培育基金(No.705045)资助项目
关键词 糖尿病心肌病 动物模型 链脲佐菌素 diabetic cardiomyopathy, animal model, streptozotocin
作者简介 张春虹,女,博士,主治医师
  • 相关文献

参考文献13

  • 1Rossi E. Cardiovascular disease in diabetes and operative risk. Rays,1997,22(4) : 595-602
  • 2Pas AK. Specific heart muscle disease in diabetes mellitus a functional structural conelation. Int J Cardiol, 1987, 17:299-302
  • 3David SH. Diabetic cardiomyopathy a unique entity or a complication of coronary artery disease. Diabetes Care, 1995,18 : 708
  • 4Schannwell CM, Schoebel FC, Heggen S, et al. Early decrease in diastolic function in young type Ⅰ diabetic patients as an initial manifestation of diabetic cardiomyopathy. Z Kardiol, 1999,88(5):338
  • 5Di Bello V, Glampietro O, Matteucci E, et al. Ultrasonic tissue characterization analysis in type 1 diabetes: a very early index of diabetic cardiomyopathy? G Ital Cardiol, 1998,28(10) : 1128-1137
  • 6Pandit SV, Giles WR, Demir SS. A mathematical model of the electrophysiological alterations in rat ventricular myocytes in type-Ⅰ diabetes. Biophy J,2003,84:832-841
  • 7Kwon NS.Nitric oxide generation from strep tozotocin. FASEB J, 1994,8 : 529
  • 8Kroncke KD, Seyler H. Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage. Biol Chem, 1995,376:379
  • 9Thomas G, Ramwell P. Streptozotocin: a nitric oxide carrying molecule and its effect on vasodilation. Eur J Pharmacol, 1989, 61:79
  • 10Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res, 2001,50:537

同被引文献264

引证文献38

二级引证文献204

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部